Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic effect of Avonex, Rebif and Betaferon on disability and quality of life in multiple sclerosis
IRCT201404195280N16Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of interferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Disability progression and Quality of life. Started Jul 2006; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT201404195280N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201404195280N16.